Latest News & Updates
New Protocol Updates Available For The National Gold Card Program
September 20, 2024
UnitedHealthcare remains committed to modernizing the prior authorization process and simplifying the health care experience for consumers and health care professionals. Our UnitedHealthcare National Gold Card program is available for provider groups who meet eligibility requirements. The National Gold Card program recognizes qualified practices that have consistently demonstrated adherence to evidence-based guidelines.
FDA approves atezolizumab and hyaluronidase-tqjs for subcutaneous injection
September 12, 2024
On September 12, 2024, the Food and Drug Administration approved atezolizumab and hyaluronidase-tqjs (Tecentriq Hybreza, Genentech, Inc.) for subcutaneous injection for all the adult indications as the intravenous formulation of atezolizumab (Tecentriq, Genentech, Inc.), including non-small cell lung cancer (NSCLC), small cell lung cancer (SCLC), hepatocellular carcinoma (HCC), melanoma, and alveolar soft part sarcoma (ASPS)….
Prescription for Change: Doctors Cast Their Votes for a Healthier Future
August 28, 2024
As oncologists, you are at the forefront of our community’s well-being. This election season, your vote can make a significant impact on the future of cancer care. Your daily encounters with patients provide you with a unique perspective on the healthcare system’s strengths and weaknesses. Voting is not just a civic duty; by exercising your…
Centers for Medicare & Medicaid Services (CMS) Releases the First Ten Drug Prices Negotiated in IRA Process for Part D
August 28, 2024
The Biden-Harris Administration announced that it has reached agreements for new, lower prices for all 10 drugs selected for negotiations. According to CMS, these negotiated drugs are some of the most expensive and most frequently dispensed drugs in the Medicare program and are used to treat conditions such as heart disease, diabetes, and cancer. The…
FDA approves selpercatinib for RET fusion-positive medullary thyroid cancer
September 29, 2024
On September 27, 2024, the Food and Drug Administration granted traditional approval to selpercatinib (Retevmo, Eli Lilly and Company) for adult and pediatric patients 2 years of age and older with advanced or metastatic medullary thyroid cancer (MTC) with a RET mutation, as detected by an FDA-approved test, who require systemic therapy.
FDA approves osimertinib for locally advanced, unresectable (stage III) non-small cell lung cancer following chemoradiation therapy | FDA
September 25, 2024
On September 25, 2024, the Food and Drug Administration approved osimertinib (Tagrisso, AstraZeneca Pharmaceuticals) for adult patients with locally advanced, unresectable (stage III) non-small cell lung cancer (NSCLC) whose disease has not progressed during or following concurrent or sequential platinum-based chemoradiation therapy and whose tumors have EGFR exon 19 deletions or exon 21 L858R mutations,…
FDA approves isatuximab-irfc with bortezomib, lenalidomide, and dexamethasone for newly diagnosed multiple myeloma
September 20, 2024
On September 20, 2024, the Food and Drug Administration approved isatuximab-irfc (Sarclisa, Sanofi-Aventis U.S. LLC) with bortezomib, lenalidomide, and dexamethasone for adults with newly diagnosed multiple myeloma who are not eligible for autologous stem cell transplant (ASCT).
FDA approves amivantamab-vmjw with carboplatin and pemetrexed for non-small cell lung cancer with EGFR exon 19 deletions or L858R mutations | FDA
September 19, 2024
On September 19, 2024, the Food and Drug Administration approved amivantamab-vmjw (Rybrevant, Janssen Biotech, Inc.) with carboplatin and pemetrexed for adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 L858R substitution mutations whose disease has progressed on or after treatment…
Get More from FLASCO With Your Partnership
The Corporate Partnership Program allows FLASCO to expand our offerings to our partneres. Every FLASCO meeting also provides the industry representative with opportunities to educate our partners. When you send representatives to a FLASCO meeting, you are allowing them to share their knowledge, as well as receive the same knowledge as our members by participating within the educational sessions. This helps ensure that the hematology and oncology community at large are learning, sharing best practices, and finding solutions to problems together.
Corporate Partners
Upcoming Events
Click to view full events calendar.
October 9, 2024 5:30 pm
FLASCO Oncology Burnout Webinar
October 12, 2024 8:00 am
FLASCO Clinical Oncology Series: GI Cancer
October 17, 2024 5:30 pm
LGBTQIA+ Living With Cancer
We're Here to Help Contact Us
Add your name, email & message below:
